Danaher(US:DHR) Yahoo Finance·2026-01-07 11:21Company Overview - Danaher Corporation (DHR) is a Washington, D.C.-based company that designs, manufactures, and markets professional, medical, research, and industrial products and services, with a market cap of $162.7 billion [1]. Earnings Expectations - Analysts anticipate that DHR will report a profit of $2.14 per share on a diluted basis for the fiscal fourth quarter of 2025, which is unchanged from the same quarter last year [2]. - For the full fiscal year, analysts expect DHR to report an EPS of $7.71, reflecting a 3.1% increase from $7.48 in fiscal 2024, and an expected rise to $8.38 in fiscal 2026, representing an 8.7% year-over-year growth [3]. Stock Performance - DHR stock has underperformed compared to the S&P 500 Index, which gained 16.2% over the past 52 weeks, with DHR shares down slightly during this period. It also underperformed the Health Care Select Sector SPDR Fund, which returned 13.7% in the same timeframe [4]. Market Challenges - The underperformance of Danaher is attributed to a cautious outlook amid uncertainties, including challenges from China's policy and restrained spending in life sciences. Management anticipates a modest recovery in bioprocessing and diagnostics while working to mitigate the impacts of China's volume-based procurement and localize manufacturing [5]. Recent Financial Results - On October 21, 2025, DHR shares rose by 5.9% following the release of Q3 results, where the adjusted EPS of $1.89 exceeded Wall Street expectations of $1.71. The company's revenue reached $6.1 billion, surpassing forecasts of $6 billion. DHR expects full-year adjusted EPS to be in the range of $7.70 to $7.80 [6]. Analyst Ratings - The consensus opinion among analysts on DHR stock is bullish, with a "Strong Buy" rating overall. Out of 23 analysts, 18 recommend a "Strong Buy," one suggests a "Moderate Buy," and four give a "Hold." The average analyst price target for DHR is $258.24, indicating a potential upside of 9.2% from current levels [7].